1
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Neoadjuvant chemotherapy in the management of advanced epithelial ovarian cancer

&
Pages 321-329 | Published online: 10 Jan 2014
 

Abstract

Epithelial ovarian cancer has the highest morbidity of all gynecologic cancers in the USA. In 2006, it is estimated that 20,180 new cases will have been diagnosed and 15,310 women will have died from ovarian cancer. Most patients are diagnosed with advanced-stage disease (stage III and IV). The conventional initial management of the disease involves a combination of aggressive cytoreductive surgery followed by chemotherapy regimens that include a platinum and taxane drug. Retrospective reviews correlate survival with the size of the residual tumor at the end of the initial surgery. For patients who are poor surgical candidates and for those who are unlikely to be optimally surgically cytoreduced, treatment with chemotherapy prior to any surgery (i.e., neoadjuvant chemotherapy) has been proposed to increase the feasibility of the subsequent surgical debulking and to decrease perioperative morbidity. There is a lack of consensus in studies assessing survival outcomes after neoadjuvant chemotherapy. In stage IV disease, neoadjuvant chemotherapy may offer a survival advantage. This article will review the current standards of care for women with advanced ovarian cancer, including primary cytoreductive surgery and interval debulking surgery. It will focus on the role of neoadjuvant chemotherapy in managing advanced-stage epithelial ovarian cancer in the current literature.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.